MedTrace Logo

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

NCT04500847 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-05-04

No results posted yet for this study

Summary

This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.

Conditions

Interventions

DRUG

Emtriva Capsule

200mg daily oral dose

DRUG

Placebo

200mg daily oral dose

Sponsors & Collaborators

  • Alzheimer's Association

    collaborator OTHER

  • Brown University

    collaborator OTHER

  • The Miriam Hospital

    collaborator OTHER

  • Cedars Sinai Medical Center, Los Angeles, USA

    collaborator UNKNOWN

  • Butler Hospital

    lead OTHER

Principal Investigators

  • Meghan Riddle, MD · Butler Hospital

  • John Sedivy, PhD · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-17
Primary Completion
2026-03-31
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04500847 on ClinicalTrials.gov